AU2022409746B2 - Personalized cancer therapy targeting normally non-expressed sequences - Google Patents

Personalized cancer therapy targeting normally non-expressed sequences

Info

Publication number
AU2022409746B2
AU2022409746B2 AU2022409746A AU2022409746A AU2022409746B2 AU 2022409746 B2 AU2022409746 B2 AU 2022409746B2 AU 2022409746 A AU2022409746 A AU 2022409746A AU 2022409746 A AU2022409746 A AU 2022409746A AU 2022409746 B2 AU2022409746 B2 AU 2022409746B2
Authority
AU
Australia
Prior art keywords
hsap38
mmus38
brain
tissue
chr8
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2022409746A
Other languages
English (en)
Other versions
AU2022409746A1 (en
Inventor
Pablo GARCES
Christian Garde
Emma Christine JAPPE
Jens Vindahl KRINGELUM
Thomas TROLLE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evaxion Biotech AS
Original Assignee
Evaxion Biotech AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evaxion Biotech AS filed Critical Evaxion Biotech AS
Publication of AU2022409746A1 publication Critical patent/AU2022409746A1/en
Application granted granted Critical
Publication of AU2022409746B2 publication Critical patent/AU2022409746B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30—Detection of binding sites or motifs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Primary Health Care (AREA)
  • Public Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
AU2022409746A 2021-12-17 2022-12-16 Personalized cancer therapy targeting normally non-expressed sequences Active AU2022409746B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21215594.9 2021-12-17
EP21215594 2021-12-17
EP22187561.0 2022-07-28
EP22187561 2022-07-28
PCT/EP2022/086444 WO2023111306A1 (en) 2021-12-17 2022-12-16 Personalized cancer therapy targeting normally non-expressed sequences

Publications (2)

Publication Number Publication Date
AU2022409746A1 AU2022409746A1 (en) 2024-07-04
AU2022409746B2 true AU2022409746B2 (en) 2025-12-04

Family

ID=84943771

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022409746A Active AU2022409746B2 (en) 2021-12-17 2022-12-16 Personalized cancer therapy targeting normally non-expressed sequences

Country Status (6)

Country Link
US (1) US20250054576A1 (https=)
EP (1) EP4449420A1 (https=)
JP (1) JP2025500926A (https=)
AU (1) AU2022409746B2 (https=)
CA (1) CA3241220A1 (https=)
WO (1) WO2023111306A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025158034A1 (en) 2024-01-24 2025-07-31 Evaxion Biotech A/S Method for optimizing selection of an effective vaccine agent

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
CA3058807A1 (en) * 2017-04-03 2018-10-11 Biontech Us Inc. Protein antigens and uses thereof
WO2020141207A1 (en) 2019-01-03 2020-07-09 Evaxion Biotech Aps Vaccines targeting neoepitopes
US20220184191A1 (en) 2019-03-11 2022-06-16 Evaxion Biotech A/S Nucleic acid vaccination using neo-epitope encoding constructs
EP3994156A1 (en) 2019-07-05 2022-05-11 The Francis Crick Institute Limited Novel cancer antigens and methods
WO2021123232A1 (en) 2019-12-18 2021-06-24 Evaxion Biotech Aps Nucleic acid vaccination using neo-epitope encoding constructs
IT202000006973A1 (it) * 2020-04-02 2021-10-02 Istituto Naz Tumori Irccs Fondazione G Pascale Antigeni herv tumore-specifici e loro uso nella immunoterapia del cancro
US20230147574A1 (en) 2020-04-07 2023-05-11 Evaxion Biotech A/S Neoepitope immunotherapy with APC targeting unit

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SMITH CHRISTOF C. ET AL: "Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 128, no. 11, 1 November 2018 (2018-11-01), GB, pages 4804 - 4820 *

Also Published As

Publication number Publication date
JP2025500926A (ja) 2025-01-15
CA3241220A1 (en) 2023-06-22
US20250054576A1 (en) 2025-02-13
AU2022409746A1 (en) 2024-07-04
WO2023111306A1 (en) 2023-06-22
EP4449420A1 (en) 2024-10-23

Similar Documents

Publication Publication Date Title
AU2022215196B2 (en) Predicting T cell epitopes useful for vaccination
JP7801134B2 (ja) 腫瘍特異的なネオ抗原を同定する組成物および方法
JP7282834B2 (ja) 共通ネオ抗原
JP7554119B2 (ja) 共有抗原
US20210138056A1 (en) Neoepitope vaccine compositions and methods of use thereof
EP2872653B1 (en) Personalized cancer vaccines and adoptive immune cell therapies
CA3110923A1 (en) Process for preparing vaccine compositions
JP2025157393A (ja) Ｈｉｖ抗原及びｍｈｃ複合体
US20260094669A1 (en) Epitope prediction via a learned genotype network across class ii mhc alleles
WO2021119545A1 (en) Durable vaccination
KR20250031143A (ko) 개인맞춤형 항암백신 개발을 위한 신항원 선정 방법
CN115803049A (zh) 抗原编码盒
AU2022409746B2 (en) Personalized cancer therapy targeting normally non-expressed sequences
BR112021006941A2 (pt) Antígenos de câncer inovadores e métodos
AU2018206769B2 (en) Compositions and methods of identifying tumor specific neoantigens
CN118974832A (zh) 靶向正常非表达序列的个性化癌症疗法
WO2025158034A1 (en) Method for optimizing selection of an effective vaccine agent
HK40068529A (en) Predicting t cell epitopes useful for vaccination
CA2982971C (en) Predicting t cell epitopes useful for vaccination
EA046410B1 (ru) Иммуногенетическая скрининговая проба на рак
CN116547761A (zh) 用于制备含新肽的疫苗试剂的工艺
HK1247989B (en) Predicting t cell epitopes useful for vaccination

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)